Zobrazeno 1 - 10
of 38
pro vyhledávání: '"A. H. Loonen"'
Autor:
M. A. Veening, Shama L. Bhola, V. de Haas, J. W. Wessels, Marielle J. Wondergem, Pauline A. Merle, M. B. Mansur, Gertjan L. Kaspers, Pino J. Poddighe, W.A. Kors, A. M. Ford, Theresia M. Westers, A H Loonen
Publikováno v:
Human Pathology: Case Reports, Vol 11, Iss, Pp 34-38 (2018)
Poddighe, P J, Veening, M A, Mansur, M B, Loonen, A H, Westers, T M, Merle, P A, Wessels, J W, de Haas, V, Kors, W A, Bhola, S L, Wondergem, M J, Ford, A M & Kaspers, G J L 2018, ' A novel cryptic CBFB-MYH11 gene fusion present at birth leading to acute myeloid leukemia and allowing molecular monitoring for minimal residual disease ', Human Pathology: Case Reports, vol. 11, pp. 34-38 . https://doi.org/10.1016/j.ehpc.2017.09.001
Human Pathology: Case Reports, 11, 34-38. Elsevier Inc.
Poddighe, P J, Veening, M A, Mansur, M B, Loonen, A H, Westers, T M, Merle, P A, Wessels, J W, de Haas, V, Kors, W A, Bhola, S L, Wondergem, M J, Ford, A M & Kaspers, G J L 2018, ' A novel cryptic CBFB-MYH11 gene fusion present at birth leading to acute myeloid leukemia and allowing molecular monitoring for minimal residual disease ', Human Pathology: Case Reports, vol. 11, pp. 34-38 . https://doi.org/10.1016/j.ehpc.2017.09.001
Human Pathology: Case Reports, 11, 34-38. Elsevier Inc.
Acute myeloid leukemia (AML) with the inv(16)/t(16;16) karyotype is associated with a favourable prognosis, showing longer periods of complete remission and high overall survival rates. Here we report a four year old girl, who presented with pallor,
Autor:
Willemijn van den Ancker, Shama L. Bhola, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Theresia M. Westers, A H Loonen, David C. de Leeuw
Publikováno v:
de Leeuw, D C, van den Ancker, W, Westers, T M, Loonen, A H, Bhola, S L, Ossenkoppele, G J & van de Loosdrecht, A A 2011, ' Challenging diagnosis in a patient with clear lymphoid immunohistochemical features and myeloid morphology: Mixed phenotype acute leukemia with erythrophagocytosis ', Leukemia Research, vol. 35, no. 5, pp. 693-696 . https://doi.org/10.1016/j.leukres.2011.01.024
Leukemia Research, 35(5), 693-696. Elsevier Limited
Leukemia Research, 35(5), 693-696. Elsevier Limited
Autor:
Brenda Gibson, Jacqueline Cloos, Ursula Creutzig, Desiree de Lange, Gertjan J.L. Kaspers, Dirk Reinhardt, Karel Hählen, Christian M. Zwaan, A H Loonen, Bianca F. Goemans
Publikováno v:
Leukemia Research, 34(10), 1302-1307. Elsevier Limited
Leukemia Research, 34, 1302-1307. Elsevier Ltd.
Goemans, B F, Zwaan, C M, Cloos, J, de Lange, D, Loonen, A H, Reinhardt, D, Hahlen, K, Gibson, B E S, Creutzig, U & Kaspers, G J L 2010, ' FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657 ', Leukemia Research, vol. 34, no. 10, pp. 1302-1307 . https://doi.org/10.1016/j.leukres.2010.04.004
Leukemia Research, 34, 1302-1307. Elsevier Ltd.
Goemans, B F, Zwaan, C M, Cloos, J, de Lange, D, Loonen, A H, Reinhardt, D, Hahlen, K, Gibson, B E S, Creutzig, U & Kaspers, G J L 2010, ' FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657 ', Leukemia Research, vol. 34, no. 10, pp. 1302-1307 . https://doi.org/10.1016/j.leukres.2010.04.004
New treatment strategies to improve the outcome of pediatric acute myeloid leukemia (AML) are required as 40% of children diagnosed with AML do not survive. Around 30% of pediatric AML patients harbour a mutation in the tyrosine kinases FLT3 (+/-20%)
Autor:
G. E. Janka-Schaub, R. X de Menezes, W A G Stams, E. R. Van Wering, M L den Boer, Rob Pieters, A. H. Loonen, E van Drunen, N L Ramakers-van-Woerden, R L Stigter, H B Beverloo
Publikováno v:
Leukemia, 20, 410-416. Nature Publishing Group
Clinical heterogeneity within t(12;21) or TEL/AML1-positive ALL (25% of childhood common/preB ALL) indicates that additional genetic changes might contribute to outcome. We studied the relation between additional genetic changes in TEL(ETV6) and AML1
Autor:
A H Loonen, Christian M. Zwaan, Bianca F. Goemans, Dirk Reinhardt, Karel Hählen, Gertjan J.L. Kaspers, Amy Harlow, Brenda Gibson, Ursula Creutzig, Michael Heinrich
Publikováno v:
Blood, 106(10), 3532-3537. American Society of Hematology
Goemans, B F, Zwaan, C M, Harlow, A, Loonen, A H, Gibson, B E S, Hählen, K, Reinhardt, D, Creutzig, U, Heinrich, M C & Kaspers, G J L 2005, ' In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib : Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets ', Blood, vol. 106, no. 10, pp. 3532-3537 . https://doi.org/10.1182/blood-2005-04-1640
Goemans, B F, Zwaan, C M, Harlow, A, Loonen, A H, Gibson, B E S, Hählen, K, Reinhardt, D, Creutzig, U, Heinrich, M C & Kaspers, G J L 2005, ' In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib : Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets ', Blood, vol. 106, no. 10, pp. 3532-3537 . https://doi.org/10.1182/blood-2005-04-1640
Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia. We tested 52
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
Autor:
Michael Heinrich, Ch. M. Zwaan, A H Loonen, Amy Harlow, Soheil Meshinchi, Gertjan J.L. Kaspers, Dirk Reinhardt, Karel Hählen, U Creutzig, M. Miller, Bianca F. Goemans, Martin Zimmermann
Publikováno v:
Leukemia, 19(9), 1536-1542. Nature Publishing Group
Goemans, B F, Zwaan, C M, Miller, M, Zimmermann, M, Harlow, A, Meshinchi, S, Loonen, A H, Hahlen, K, Reinhardt, D, Creutzig, U, Kaspers, G J L & Heinrich, M C 2005, ' Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia ', Leukemia, vol. 19, no. 9, pp. 1536-1542 . https://doi.org/10.1038/sj.leu.2403870
Goemans, B F, Zwaan, C M, Miller, M, Zimmermann, M, Harlow, A, Meshinchi, S, Loonen, A H, Hahlen, K, Reinhardt, D, Creutzig, U, Kaspers, G J L & Heinrich, M C 2005, ' Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia ', Leukemia, vol. 19, no. 9, pp. 1536-1542 . https://doi.org/10.1038/sj.leu.2403870
Activating mutations in RAS and receptor tyrosine kinases such as KIT and FLT3 are hypothesized to cooperate with chimeric transcription factors in the pathogenesis of acute myeloid leukemia (AML). To test this hypothesis, we genotyped 150 pediatric
Publikováno v:
Cancer Research. 65:291-299
To investigate the effect of l-asparaginase on acute lymphoblastic leukemia (ALL), we used cDNA microarrays to obtain a genome-wide view of gene expression both at baseline and after in vitro exposure to l-asparaginase in cell lines and pediatric ALL
Autor:
M L den Boer, Jochen Harbott, E. R. Van Wering, A H Loonen, Bruce M. Camitta, G. E. Janka-Schaub, Rosalyn Slater, W.-D. Ludwig, Rob Pieters, N L Ramakers-van Woerden, Anjo J.P. Veerman, H B Beverloo, Oskar A. Haas
Publikováno v:
Leukemia, 18(3), 521-9. Nature Publishing Group
Ramakers-van Woerden, NL, Beverloo, HB, Veerman, A J P, Camitta, BM, Loonen, A H, van Wering, E R, Slater, RM, Harbott, J, den Boer, M L, Ludwig, WD, Haas, OA & Janka-Schaub, GE 2004, ' In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. ', Leukemia, vol. 18, no. 3, pp. 521-9 . https://doi.org/10.1038/sj.leu.2403253
Leukemia, 18, 521-529. Nature Publishing Group
Ramakers-van Woerden, NL, Beverloo, HB, Veerman, A J P, Camitta, BM, Loonen, A H, van Wering, E R, Slater, RM, Harbott, J, den Boer, M L, Ludwig, WD, Haas, OA & Janka-Schaub, GE 2004, ' In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. ', Leukemia, vol. 18, no. 3, pp. 521-9 . https://doi.org/10.1038/sj.leu.2403253
Leukemia, 18, 521-529. Nature Publishing Group
Acute lymphoblastic leukemia (ALL) in infants under 1 year is strongly associated with translocations involving 11q23 (MLL gene), CD10-negative B-lineage (proB) immunophenotype, and poor outcome. The present study analyses the relationship between ag
Autor:
Sonja Zweegman, Gert J. Ossenkoppele, Pauline A. Merle, A H Loonen, Marisa Westers, Pino J. Poddighe, Hans Wessels, Shama L. Bhola, Marielle J. Wondergem
Publikováno v:
Poddighe, P J, Wessels, H, Merle, P, Westers, T M, Bhola, S L, Loonen, A, Zweegman, S, Ossenkoppele, G J & Wondergem, M J 2014, ' Genomic amplification of MYC as double minutes in a patient with APL-like leukemia ', Molecular cytogenetics, vol. 7, 67 . https://doi.org/10.1186/s13039-014-0067-6
Molecular cytogenetics, 7:67. BioMed Central
Molecular Cytogenetics
Molecular cytogenetics, 7:67. BioMed Central
Molecular Cytogenetics
Background Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) characterized by a PML-RARA fusion due to a translocation t(15;17). Its sensitivity to treatment with all-trans retinoic acid (ATRA), which causes differentiat
Autor:
Marianne G. Rots, Mats Heyman, Willem Kamps, Rob Pieters, E van Drunen, A H Loonen, H B Beverloo, N. L. Ramakers-Van Woerden, TC Moreno, E. R. Van Wering, G. E. Janka-Schaub, Rosalyn Slater, A. J. P. Veerman
Publikováno v:
British Journal of Haematology. 112:680-690
p16 gene deletions are present in about 70% of primary paediatric T-cell acute lymphoblastic leukaemia (T-ALL) and 20% of common/precursor B-cell ALL cases. It is not clear what the impact of the frequent p16 deletions is within the subgroup of T-lin